GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Increasing evidence indicates that obesity is highly associated with chronic kidney disease (CKD). GLP-1 receptor (GLP-1R) agonist has shown benefits on kidney diseases, but its direct role on kidney metabolism in obesity is still not clear. This study aims to investigate the protection and metabolic modulation role of liraglutide (Lira) on kidney of obesity. Rats were induced obese by high-fat diet (HFD), and renal function and metabolism changes were evaluated by metabolomic, biological and histological methods. HFD rats exhibited systemic metabolic disorders such as obesity, hyperlipidemia and impaired glucose tolerance, as well as renal histological and function damages, while Lira significantly ameliorated these adverse effects in HFD rats. Metabolomic data showed that Lira directly reduced renal lipids including fatty acid residues, cholesterol, phospholipids and triglycerides, and improved mitochondria metabolites such as succinate, citrate, taurine, fumarate and nicotinamide adenine dinucleotide (NAD+) in the kidney of HFD rats. Furthermore, we revealed that Lira inhibited renal lipid accumulation by coordinating lipogenic and lipolytic signals, and partly rescued renal mitochondria function via Sirt1/AMPK/PGC1α pathways in HFD rats. This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below.”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [71]
In the citing paper
“They minimize renal hypoxic-ischaemic damage as they regulate the mitochondrial activity of renal cells [40];”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241
Novel insights of dietary polyphenols and obesity
Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I., & Shen, C.-L. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.001 · Cited by 896
Obesity and Risk of Type 2 Diabetes and Cardiovascular Disease in Children and Adolescents
Goran, M. I., Ball, G. D. C., & Cruz, M. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021442 · Cited by 735
Association between obesity and kidney disease: A systematic review and meta-analysis
Wang, Y., Chen, X., Song, Y., Caballero, B., & Cheskin, L. J. (2008) · Kidney International · doi:10.1038/sj.ki.5002586 · Cited by 687
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease
Sharma, K., Karl, B., Mathew, A. V., Gangoiti, J. A., Wassel, C. L., Saito, R., Pu, M., Sharma, S., You, Y.-H., Wang, L., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020126 · Cited by 571
Association Between Body Mass Index and CKD in Apparently Healthy Men
Gelber, R. P., Kurth, T., Kausz, A. T., Manson, J. E., Buring, J. E., Levey, A. S., & Gaziano, J. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.015 · Cited by 460
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
Weinberg, J. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001834 · Cited by 371
L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent
Zhong, Z., Wheeler, M. D., Li, X., Froh, M., Schemmer, P., Yin, M., Bunzendaul, H., Bradford, B., & Lemasters, J. J. (2003) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200303000-00013 · Cited by 370
Renal lipid metabolism and lipotoxicity
Bobulescu, I. A. (2010) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e32833aa4ac · Cited by 364
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Andersen, K., Kesper, M. S., Marschner, J. A., Konrad, L., Ryu, M., Kumar VR, S., Kulkarni, O. P., Mulay, S. R., Romoli, S., Demleitner, J., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111285 · Cited by 266
Regulation of lipid accumulation by AMK-activated kinase in high fat diet–induced kidney injury
Declèves, A.-E., Zolkipli, Z., Satriano, J., Wang, L., Nakayama, T., Rogac, M., Le, T. P., Nortier, J. L., Farquhar, M. G., Naviaux, R. K., et al. (2014) · Kidney International · doi:10.1038/ki.2013.462 · Cited by 231
Obesity in CKD—What Should Nephrologists Know?
Stenvinkel, P., Zoccali, C., & Ikizler, T. A. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040330 · Cited by 220
Effects of weight loss on renal function in obese CKD patients: a systematic review
Bolignano, D., & Zoccali, C. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft302 · Cited by 211
Wu, L. L., Cox, A., Roe, C. J., Dziadek, M., Cooper, M. E., & Gilbert, R. E. (1997) · Kidney International · doi:10.1038/ki.1997.214 · Cited by 209
Raun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2007) · Diabetes · doi:10.2337/db06-0565 · Cited by 207
Consoli, A., Nurjhan, N., Reilly, J. J., Bier, D. M., & Gerich, J. E. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114940 · Cited by 204
Mima, A., Hiraoka-Yamomoto, J., Li, Q., Kitada, M., Li, C., Geraldes, P., Matsumoto, M., Mizutani, K., Park, K., Cahill, C., et al. (2012) · Diabetes · doi:10.2337/db11-1824 · Cited by 203
Xu, S., Nam, S. M., Kim, J.-H., Das, R., Choi, S.-K., Nguyen, T. T., Quan, X., Choi, S. J., Chung, C. H., Lee, E. Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.331 · Cited by 199
Thethi, T., Kamiyama, M., & Kobori, H. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0245-z · Cited by 178
GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 158
Impaired protein metabolism: interlinks between obesity, insulin resistance and inflammation
Guillet, C., Masgrau, A., Walrand, S., & Boirie, Y. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01037.x · Cited by 118
SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114
Nosadini, R., & Tonolo, G. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.10.002 · Cited by 109
Takashima, S., Fujita, H., Fujishima, H., Shimizu, T., Sato, T. K., Morii, T., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.012 · Cited by 107
Obesity Related Kidney Disease
Mathew, A. V., Okada, S., & Sharma, K. (2011) · Current Diabetes Reviews · doi:10.2174/157339911794273928 · Cited by 101
Mitochondrial alteration in type 2 diabetes and obesity: An epigenetic link
Cheng, Z., & Almeida, F. (2014) · Cell Cycle · doi:10.4161/cc.28189 · Cited by 94
Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury
Cao, Z., Cooper, M. E., Wu, L. L., Cox, A. J., Jandeleit-Dahm, K. A. M., Kelly, D. J., & Gilbert, R. E. (2000) · Hypertension · doi:10.1161/01.hyp.36.4.561 · Cited by 92
Liu, J., Wang, C., Liu, F., Lu, Y., & Cheng, J. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8481-0 · Cited by 86
Self-citationChung, H. W., Lim, J. H., Kim, M. Y., Shin, S. J., Chung, S., Choi, B. S., Kim, H. W., Kim, Y.-S., Park, C. W., & Chang, Y. S. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr613 · Cited by 82
Katagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 80
Mitochondrial Plasticity in Obesity and Diabetes Mellitus
Jelenik, T., & Roden, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4910 · Cited by 73
Yin, Q.-H., Zhang, R., Li, L., Wang, Y.-T., Liu, J.-P., Zhang, J., Bai, L., Cheng, J.-Q., Fu, P., & Liu, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.730564 · Cited by 66
Self-citationLiu, S., Yuan, Y., Zhou, Y., Zhao, M., Chen, Y., Cheng, J., Lu, Y., & Liu, J. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13176 · Cited by 59
Self-citationFrederico, M. J. S., Vitto, M. F., Cesconetto, P. A., Engelmann, J., de Souza, D. R., da Luz, G., Pinho, R. A., Ropelle, E. R., Cintra, D. E., & de Souza, C. T. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.613945 · Cited by 55
The role of taurine in renal disorders
Han, X., & Chesney, R. W. (2012) · Amino Acids · doi:10.1007/s00726-012-1314-y · Cited by 50
Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
Hocher, B., & Tsuprykov, O. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.140 · Cited by 35
Einbinder, Y., Ohana, M., Benchetrit, S., Zehavi, T., Nacasch, N., Bernheim, J., & Zitman‐Gal, T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2801 · Cited by 23
Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury
Muenter, K., & Dashwood, M. R. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.e13 · Cited by 9
Toblli, J. E., Cao, G., Rico, L., & Angerosa, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s151162 · Cited by 8
Cited by
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
“In high-fat diet rats (HFD), liraglutide restored kidney mitochondrial function counteracting the decline of biogenesis of genes encoding for proteins of mitochondrial respiration and increasing the uncoupling protein 2 levels [30].”
BackgroundObesity and chronic kidney disease: A current review
Nawaz, S., Chinnadurai, R., Al‐Chalabi, S., Evans, P., Kalra, P. A., Syed, A. A., & Sinha, S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.629 · Cited by 168
“iting renal lipid accumulation and rescued renal mitochondria function after inducing obesity in rats using a high fat diet.(146) These data are encouraging to consider GLP‐1 RAs in people with obesity and”
BackgroundKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Metadata
- Authors
- Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Lu, Yanrong
- Liu, Jingping
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-03-28
- Volume
- 13
- Issue
- 3
- Pages
- e0193473
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5873987
- OpenAlex
- W2795005430
- Cited by
- 110
- References
- 48
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 1
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (31200754, 81571808)
- China Postdoctoral Science Foundation (2012M511931)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, liraglutide, obesity, chronic kidney disease, renal metabolism, high-fat diet, renal lipid accumulation, mitochondrial function, hyperlipidemia, impaired glucose tolerance
- MeSH terms
- Liraglutide, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Fibrosis, Homeostasis, Kidney, Male, Mitochondria, Obesity, Signal Transduction, Rats, Sprague-Dawley, Lipid Metabolism, Rats, AMP-Activated Protein Kinases, Metabolomics, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.